mp.weixin.qq.com·· 10 hours agoPickScore85
Detailed Phase 3 Data for intismeran autogene Plus Keytruda in Melanoma Show 42% Lower Recurrence or Death Risk
In brief
Merck and Moderna have announced detailed Phase 3 results for the personalized mRNA cancer therapy intismeran autogene combined with Keytruda (pembrolizumab) in melanoma. Compared with Keytruda alone, the combination reduced the risk of disease recurrence or death by 42%.
Why it matters
The brief gives the specific 42% reduction in recurrence or death risk versus Keytruda alone, comparable to existing readouts in melanoma adjuvant therapy.
Source: mp.weixin.qq.com · mp.weixin.qq.com